Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $36.51M
• Dividend Yield: N/A
• Average Volume (3M): 313.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: -12.99%
• EPS Growth: -13.67%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 16,673,126
• 10 Day Avg. Volume: 386,865
• 30 Day Avg. Volume: 313,176
• PEG Ratio: 0.07
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 4.24
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: -0.11
• Enterprise Value/Revenue: -0.85
• Enterprise Value/Gross Profit: 0.52
• Enterprise Value/Ebitda: 0.39
• 1Y Price Target: $9.00
• Price Target Upside: 334.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $2.00 ▼(-3.38% Downside)

The score is held down primarily by weak financial performance (shrinking revenue, very large losses, and persistent cash burn) and limited valuation support (negative P/E due to losses, no dividend). Technicals are a partial offset with strong trend strength, though overbought readings raise the risk of a near-term pullback.

Positive Factors

Clean balance sheet (no debt)

Zero reported debt materially reduces solvency and refinancing risk for a cash-burning clinical-stage biotech. This affords the company flexibility to fund trials via equity or partnerships, preserves borrowing optionality, and lowers default risk over the next 2–6 months.

MultiTAA T‑cell development platform

A platform targeting multiple tumor antigens is a durable strategic advantage: it can address tumor heterogeneity, broaden indication potential across solid tumors and hematologic malignancies, and enable multi-program pipelines that support long-term value creation if clinical proof emerges.

Improving free cash flow trend

A 36% improvement in TTM free cash flow signals operational efficiency gains and better cash conversion relative to prior periods. While absolute burn remains, this trajectory can extend runway and reduce near-term financing pressure if the improvement continues through upcoming quarters.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow around -$14.8M annually is a durable funding constraint for a clinical-stage developer; it necessitates recurring capital raises or partnerships, which can dilute shareholders and create execution risk for ongoing trials and development programs.

Declining revenue and large losses

Falling revenue and extremely negative net margins (~-305%) indicate the business is far from break-even and eroding equity returns. Over the medium term this constrains reinvestment capacity, heightens reliance on external funding, and raises the bar for clinical success to justify further investment.

Very small employee base

Operating with only five employees limits in-house R&D, trial management, and commercialization capabilities, increasing dependence on CROs, partners, or vendors. This structural constraint raises execution risk and can slow program timelines if partnerships falter.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

How the Company Makes Money

Marker Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future product sales. Additionally, the company may receive funding from grants and research agreements to support the development of its therapeutic candidates. As a clinical-stage company, Marker Therapeutics does not yet generate revenue from product sales, as its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.

Marker Therapeutics Financial Statement Overview

Summary

Marker Therapeutics shows promising revenue growth but struggles with profitability and cash flow management. The strong cash position provides a buffer, yet the company must focus on improving operational efficiencies and reducing losses to enhance financial health and attract sustainable investment.

Income Statement

Marker Therapeutics has demonstrated consistent revenue growth over the years, culminating in a significant increase in TTM (Trailing-Twelve-Months) revenue. However, this growth is overshadowed by substantial net losses and negative EBIT and EBITDA margins, indicating persistent profitability challenges.

Balance Sheet

The company maintains a strong cash position with zero debt as of the latest report, which enhances its financial stability. However, the negative equity ratio over time and significant net losses are concerning, reflecting a need for improved operational efficiency.

Cash Flow

Marker Therapeutics is experiencing negative operating and free cash flow, indicating cash burn which is common in early-stage biotechs. The positive financing cash flow suggests external funding reliance, which could pose future financial risks if not managed properly.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.69M	6.59M	3.31M	3.51M	1.24M	466.79K
Gross Profit	-7.70M	-6.88M	-7.11M	-8.45M	-1.92M	-18.41M
EBITDA	-10.12M	-11.12M	-11.79M	-17.00M	-38.72M	-27.63M
Net Income	-14.30M	-10.73M	-8.24M	-29.93M	-41.88M	-28.71M
Balance Sheet
Total Assets	21.73M	22.02M	17.13M	34.42M	68.14M	45.61M
Cash, Cash Equivalents and Short-Term Investments	17.59M	19.19M	15.11M	11.78M	42.35M	21.35M
Total Debt	0.00	0.00	0.00	7.62M	11.87M	12.26M
Total Liabilities	3.35M	3.46M	3.07M	14.82M	24.15M	18.27M
Stockholders Equity	18.39M	18.56M	14.05M	19.60M	43.99M	27.34M
Cash Flow
Free Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-30.41M	-29.29M
Operating Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-27.28M	-20.03M
Investing Cash Flow	0.00	0.00	18.66M	-4.95M	-3.13M	-9.25M
Financing Cash Flow	24.76M	14.99M	1.11M	202.13K	52.56M	6.74M

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Positive. The current price of 2.07 is above the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.25, and above the 200-day MA of 1.23, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 73.85 is Negative, neither overbought nor oversold. The STOCH value of 82.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	54 Neutral	$48.80M	-1.69	-54.50%	―	185.71%	79.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRKR	49 Neutral	$36.51M	-1.68	-110.67%	―	-12.99%	-13.67%
ADXN	46 Neutral	$9.32M	-0.92	-71.27%	―	-72.15%	-223.62%
MBRX	44 Neutral	$12.53M	-0.07	―	―	―	79.31%
ABVC	44 Neutral	$56.14M	-10.09	-40.32%	―	56.52%	75.22%
ALLR	42 Neutral	$18.63M	-0.74	-122.61%	―	―	99.82%